Poor in vivo efficacy of caspofungin, micafungin and amphotericin B against wild-type Candida krusei clinical isolates does not correlate with in vitro susceptibility results

Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia

(2017) Carlo Tascini et al.   JOURNAL OF CHEMOTHERAPY

Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use

(2017) Franco Aversa et al.   JOURNAL OF CHEMOTHERAPY

Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

(2016) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Invasive fungal infection in neonatal intensive care units: a multicenter survey

(2016) Monica Isabel Baptista et al.   JOURNAL OF CHEMOTHERAPY

Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients

(2015) Vincent J. Lempers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality

(2015) Emily Wang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis

(2015) S. Grau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dose escalation studies with caspofungin against Candida glabrata

(2015) Marianna Domán et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Tissue Penetration of Antifungal Agents

(2014) T. Felton et al.   CLINICAL MICROBIOLOGY REVIEWS

Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management

(2014) David S. Perlin   DRUGS

Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period

(2014) Arnaldo L. Colombo et al.   INTENSIVE CARE MEDICINE

Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010)

(2014) Olivier Lortholary et al.   INTENSIVE CARE MEDICINE

Comparison of effects of human serum and horse serum onin vitrosusceptibility testing of echinocandins

(2014) Anna Prigitano et al.   JOURNAL OF CHEMOTHERAPY

Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?

(2013) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua

(2013) R. Kovacs et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time–kill methodology

(2012) Richárd Földi et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008

(2012) Michael Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin againstCandida speciesusing time-kill methodology

(2012) Judit Szilágyi et al.   JOURNAL OF CHEMOTHERAPY

Comparison of In Vitro and Vivo Efficacy of Caspofungin Against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans

(2012) Richárd Földi et al.   MYCOPATHOLOGIA

Efficacy of Caspofungin in a Juvenile Mouse Model of Central Nervous System Candidiasis

(2011) Amy M. Flattery et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

(2011) O. A. Cornely et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis

(2011) N. Undre et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Distribution of micafungin in the tissue fluids of patients with invasive fungal infections

(2011) Noriaki Yamada et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies

(2010) Naoe Goto et al.   AMERICAN JOURNAL OF HEMATOLOGY

Echinocandin Antifungal Drugs in Fungal Infections

(2010) Sharon C.-A. Chen et al.   DRUGS

Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants

(2010) Elizabeth M. Migoya et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of the New Micronaut-Candida System Compared to the API ID32C Method for Yeast Identification

(2008) Z. Szabo et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Use of a serum-based antifungal susceptibility assay to predict thein vivoefficacy of novel echinocandin compounds

(2008) Katsuyuki Maki et al.   MICROBIOLOGY AND IMMUNOLOGY